InsiderSignal.AI

InsiderSignal.ai

SAVA - Cassava Sciences Inc

Insider Purchase by Barry Richard (Pres, CEO)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Barry Richard, serving as Pres, CEO at Cassava Sciences Inc (SAVA), purchased 237,941 shares at $2.25 per share, for a total transaction value of $534,743.00. Following this transaction, Barry Richard now holds 707,503 shares of SAVA.

This purchase represents a 51.00% increase in Barry Richard's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, September 18, 2025 and publicly disclosed via SEC Form 4 filing on Monday, September 22, 2025, 4 days after the trade was made.

Cassava Sciences Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Barry Richard

Pres, CEO

Richard J. "Rick" Barry is President, Chief Executive Officer, and Class II Director at Cassava Sciences, Inc. (SAVA), a biopharmaceutical company focused on Alzheimer's disease treatments.[[1]](https://www.sarepta.com/about-us/leadership/richard-j-barry)[[2]](https://fintool.com/app/research/companies/SAVA/people/richard-barry)[[5]](https://www.marketscreener.com/insider/RICHARD-BARRY-A03GVE/) He joined the Board in June 2021, served as Executive Chairman from July 2024, and was appointed CEO on September 6, 2024, following the resignation of prior leadership amid controversies.[[1]](https://www.sarepta.com/about-us/leadership/richard-j-barry)[[2]](https://fintool.com/app/research/companies/SAVA/people/richard-barry)[[3]](https://en.wikipedia.org/wiki/Cassava_Sciences) Barry, aged 66, holds a Bachelor of Arts from Pennsylvania State University and brings over 30 years of experience in investment management.[[1]](https://www.sarepta.com/about-us/leadership/richard-j-barry)[[2]](https://fintool.com/app/research/companies/SAVA/people/richard-barry) He was a founding member, Managing General Partner, and Portfolio Manager at Eastbourne Capital Management LLC (1999–2010), a large equity hedge fund with healthcare investments, and previously served as Portfolio Manager and Managing Director at Robertson Stephens Investment Management.[[1]](https://www.sarepta.com/about-us/leadership/richard-j-barry)[[2]](https://fintool.com/app/research/companies/SAVA/people/richard-barry) His career includes roles at Lazard Freres, Legg Mason, and Merrill Lynch, plus board service at Sarepta Therapeutics (since 2015, Chair of Nominating & Governance Committee), MiMedx Group (2019–2020), and Elcelyx Therapeutics (2013–2019).[[1]](https://www.sarepta.com/about-us/leadership/richard-j-barry)[[2]](https://fintool.com/app/research/companies/SAVA/people/richard-barry)[[5]](https://www.marketscreener.com/insider/RICHARD-BARRY-A03GVE/)

View full insider profile →

Trade Price

$2.25

Quantity

237,941

Total Value

$534,743.00

Shares Owned

707,503

Trade Date

Thursday, September 18, 2025

157 days ago

SEC Filing Date

Monday, September 22, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Cassava Sciences Inc

Company Overview

No company information available
View news mentioning SAVA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/447720

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime